Clinical Trial Detail

NCT ID NCT03945721
Title A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

triple-receptor negative breast cancer

Therapies

Niraparib

Age Groups: senior adult

No variant requirements are available.